Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bast

Showing results (331-340 of 560) with videos related to

Pageof 56
Sort By:
Medical Oncology (Northwood, London, England)|June 10, 2016
Epac1 knockdown inhibits the proliferation of ovarian cancer cells by inactivating AKT/Cyclin D1/CDK4 pathway in vitro and in vivoMeng Gao, Yanyan Ma, Robert C Bast, et al.
Nuclear Medicine and Biology|January 11, 2000
Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distributionM R Zalutsky, F J Xu, Y Yu, et al.
Cells|August 27, 2025
DIRAS3 Inhibits Ovarian Cancer Cell Growth by Blocking the Fibronectin-Mediated Integrin β1/FAK/AKT Signaling PathwayJing Guo, Janice M Santiago-O'Farrill, Vivian Orellana, et al.
Oncotarget|February 3, 2017
Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cellsCharlotte Taylor, David Mannion, Fabrizio Miranda, et al.
Gynecologic Oncology|August 12, 1998
Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell linesM P Boente, A Berchuck, R S Whitaker, et al.
Molecular Cancer Research : MCR|October 12, 2014
Clinically relevant microRNAs in ovarian cancerShu Zhang, Zhen Lu, Anna K Unruh, et al.
American Journal of Obstetrics and Gynecology|September 1, 1993
Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasiasM F Kohler, H Nishii, P A Humphrey, et al.
Cancer|June 15, 1993
Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancerS J McKenzie, K A DeSombre, B S Bast, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic studyW P Peters, A Stuart, M Klotman, et al.
Cancers|January 28, 2021
A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to CarboplatinDengxuan Fan, Hailing Yang, Weiqun Mao, et al.
Pageof 56

Showing results (331-340 of 560) with videos related to

Sort By:
Pageof 56
Medical Oncology (Northwood, London, England)|June 10, 2016
Epac1 knockdown inhibits the proliferation of ovarian cancer cells by inactivating AKT/Cyclin D1/CDK4 pathway in vitro and in vivoMeng Gao, Yanyan Ma, Robert C Bast, et al.
Nuclear Medicine and Biology|January 11, 2000
Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distributionM R Zalutsky, F J Xu, Y Yu, et al.
Cells|August 27, 2025
DIRAS3 Inhibits Ovarian Cancer Cell Growth by Blocking the Fibronectin-Mediated Integrin β1/FAK/AKT Signaling PathwayJing Guo, Janice M Santiago-O'Farrill, Vivian Orellana, et al.
Oncotarget|February 3, 2017
Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cellsCharlotte Taylor, David Mannion, Fabrizio Miranda, et al.
Gynecologic Oncology|August 12, 1998
Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell linesM P Boente, A Berchuck, R S Whitaker, et al.
Molecular Cancer Research : MCR|October 12, 2014
Clinically relevant microRNAs in ovarian cancerShu Zhang, Zhen Lu, Anna K Unruh, et al.
American Journal of Obstetrics and Gynecology|September 1, 1993
Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasiasM F Kohler, H Nishii, P A Humphrey, et al.
Cancer|June 15, 1993
Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancerS J McKenzie, K A DeSombre, B S Bast, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic studyW P Peters, A Stuart, M Klotman, et al.
Cancers|January 28, 2021
A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to CarboplatinDengxuan Fan, Hailing Yang, Weiqun Mao, et al.
Pageof 56